Safe Use of Gemfibrozil inUremic Patients on Continuous Ambulatory Peritoneal Di alysis

Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End‐Stage Renal Disease

“…The dose of gemfibrozil in these studies was lower than that used in individuals with normal kidney function (600 mg/day in two studies and 600 mg every other day in the third study). Studies in CAPD patients treated with gemfibrozil have demonstrated reductions in total cholesterol and increases in HDL cholesterol in addition to lowering TGs (72,73).…”

“…While gemfibrozil and bezafibrate, used at lower doses in the above mentioned studies of patients with ESRD, were well tolerated, caution should be exercised with these drugs (70,(72)(73)(74)(78)(79)(80)(81). There are case reports of rhabdomyolysis associated with the use of different fibrates in patients with ESRD (82).…”

“…As a result, the levels of TGs and VLDL cholesterol were reduced and HDL was increased (69). In dyslipidemic patients on continuous ambulatory peritoneal dialysis (CAPD), treatment with gemfibrozil resulted in a significant reduction in TGs without evidence of muscle or liver toxicity (70–72). The dose of gemfibrozil in these studies was lower than that used in individuals with normal kidney function (600 mg/day in two studies and 600 mg every other day in the third study).…”

“…The dose of gemfibrozil in these studies was lower than that used in individuals with normal kidney function (600 mg/day in two studies and 600 mg every other day in the third study). Studies in CAPD patients treated with gemfibrozil have demonstrated reductions in total cholesterol and increases in HDL cholesterol in addition to lowering TGs (72,73). In a study comparing the effects of simvastatin and gemfibrozil (600 mg twice a day) in CAPD patients with dyslipidemia, simvastatin resulted in significantly higher degrees of reduction in TG and total cholesterol levels.…”